Daidaita Gano Cutar Alzheimer da Dementia

Diadem srl, wani kamfani da ke haɓaka gwaje-gwaje na tushen jini don farkon tsinkaya da kuma gano cutar Alzheimer (AD), a yau ya sanar da cewa ya gabatar da bayanai a taron AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD22) yana nuna cewa Sabuwar gwajin ta AlzoSure® Tabbatar da gwajin jini na iya gano daidai da marasa lafiya da cutar Alzheimer. Babban jami'in gudanarwa na Diadem Paul Kinnon ne ya gabatar da gabatarwar, "Gwajin Farko wanda ba na jini ba ne don gano cutar Alzheimer da sauran cutar hauka," a taron da aka yi a Barcelona, ​​​​Spain a ranar 19 ga Maris, 2022.

An haɓaka AlzoSure® Confirm akan dandamalin fasaha guda ɗaya wanda ke ƙarƙashin AlzoSure® Predict, gwajin jini na Diadem wanda zai iya yin hasashen daidai ko mutumin da ke da sauye-sauyen fahimi na farko zai ci gaba zuwa cutar Alzheimer har zuwa shekaru shida kafin yanayin ya bayyana. Hukumar Abinci da Magunguna ta Amurka ta ayyana AlzoSure® Hasashen Na'urar Ƙarfafawa kuma kwanan nan ya sami alamar CE-IVD da ke ba da damar tallata shi a cikin Burtaniya da Tarayyar Turai.

Sabuwar ƙididdiga ta dogara ne akan U-p53AZ mai haɗawa da biomarker - bambance-bambancen nau'i na p53 - wanda aka danganta da pathogenesis na AD a cikin fiye da nazarin 400, tare da rubuce-rubucen hulɗar tare da amyloid, tau da sauran abubuwan da ke hade da ci gaban marasa lafiya. ku AD. An haɓaka fasahar haƙƙin mallaka ta Diadem ta amfani da dandalin U-p53AZ.

A cikin binciken da aka gabatar a AD / PD22, masu binciken Diadem sun yi amfani da wani nau'i na samfurori daga bayanan bayanan da suka dace na kusan marasa lafiya 500 da ke nuna matakai daban-daban na rashin fahimta don bincika cikakken jerin gyare-gyaren bayan fassarar (PTMs) na U-p53AZ a kan hanya. na ci gaba da ya ƙare a cikin cutar Alzheimer. Sun gano cewa takamaiman PTM “hannun yatsan hannu” ko sa hannu, sun kasance halayen matakai daban-daban na ci gaban AD. AlzoSure® Confirm yana amfani da sa hannun PTM wanda ke nuna cikakkiyar cutar Alzheimer don samar da gwajin kwayar halitta na tushen jini mai yuwuwar gano AD. A cikin bayanan ingantattun bayanan asibiti na farko Diadem da aka gabatar a AD/PD22, wannan sa hannun PTM ya sami ikon gano marasa lafiya da AD kuma ya bambanta su da marasa lafiya da sauran cututtukan hauka.

"A Diadem, mun himmatu wajen samar da gwaje-gwajen jini da ake iya samun dama ga kowa da kowa wanda zai iya tantance daidaikun mutanen da ke da cutar Alzheimer ko kuma wadanda za su ci gaba zuwa AD a cikin shekaru masu zuwa," in ji Mista Kinnon. "An riga an tabbatar da gwajin gwajin jinin mu na AlzoSure® a cikin manyan karatun asibiti na dogon lokaci kuma zai kasance a cikin EU daga baya a wannan shekara. Mun kuma yi farin ciki sosai game da sabon gwajin mu na AlzoSure® Confirm, wanda ke da yuwuwar yin daidai kuma musamman gano cutar Alzheimer ta amfani da gwajin jini mai sauƙi. Rashin ingantaccen bincike na lokaci, daidai kuma mai araha ya hana ci gaba wajen haɓaka zaɓuɓɓukan magani masu inganci ga marasa lafiya AD, kuma muna fatan yin aiki tare da abokan tarayya daban-daban don samarwa da bayar da rahoton ƙarin bayanan tabbatarwa akan AlzoSure® Confirm."